Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 406-414

  Knox, Susan J ^a,h   Goris, Michael L ^a   Tempero, Margaret ^b   Weiden, Paul L ^c   Gentner, Louis ^d   Breitz, Hazel ^c   Adams, Gregory P ^e   Axworthy, Donald ^f   Gaffigan, Sally ^f   Bryan, Kyle ^f   Fisher, Darrell R ^g   Colcher, David ^b   Horak, Ivan D ^d   Weiner, Louis M ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f Poniard Pharmaceuticals Inc   (United States)

^g PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANTINEOPLASTIC AGENT; BIOTIN; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM TETRAAZACYCLODODECANE TETRAACETIC ACID BIOTIN Y 90;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTIBODIES, MONOCLONAL; BIOTIN; COLONIC NEOPLASMS; FEMALE; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; RADIOIMMUNOTHERAPY; RADIOPHARMACEUTICALS; THROMBOCYTOPENIA; YTTRIUM RADIOISOTOPES;

EID: 0033963824     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Davis, T., and Knox, S. J. Radioimmunoconjugate therapy of non-Hodgkin's lymphoma. in: L. Grossbard (ed.), Monoclonal Antibody-based Therapy of Cancer, pp. 113-136. New York: Marcel Dekker, Inc., 1998.
2. Meredith, R. F., and Knox, S. J. Radioimmunotherapy. In: J. E. Tepper and L. L. Gunderson (eds.), Clinical Radiation Oncology, Chapter 15. Edinburgh, Scotland: Churchill-Livingstone, in press, 2000.
3. Stickney, D. R., Slater, J. B., Kirk, G. A., Ahlem, C., Chang, C. H., and Frincke, J. M. Bifunctional antibody: ZCE/CHH indium-111 BLEDTA-IV clinical imaging in colorectal cancer. Antib. Immunoconjug. Radiopharm., 2: 1-13, 1989.
4. Bosslet, K., Steinstraesser, A., Hermentin, P., Kuhlman, L., Broynck, A., Magerstaedt, M., Seeman, G., Schwarz, A., and Sedlacek, H. H. Generation of bispecific monoclonal antibodies for two-phase radioimmunotherapy. In: A. A. Epenetos (ed.), Monoclonal Antibodies: Applications in Clinical Oncology, pp. 167-178. London: Chapman and Hall, 1991.
5. Chatal, J. F., Faivre-Chauvet, A., and Bardies, M. Bifunctional antibodies for radioimmunotherapy. Hybridoma, 14: 125-128, 1995.
6. Paganelli, G., Magnani, P., Siccardi, A. G., and Fazio, F. Clinical application of the avidin-biotin system for tumor targeting. In: D. M. Goldenberg (ed.), Cancer Therapy with Radiolabeled Antibodies, pp. 239-254. Boca Raton: CRC Press, Inc., 1995.
7. Paganelli, G., Magnani, P., and Fazio, F. Monoclonal antibody pretargeting techniques: the avidin-biotin system in clinical oncology. In: A. A. Epenetos (ed.), Monoclonal Antibodies 2: Applications to Clinical Oncology, pp. 171-178. London: Chapman and Hall, 1993.
8. Sinitsyn, V. V., Mamontova, A. G., Checkneva, Y. Y., Shnyra, A. A., and Domogatsky, S. P. Rapid blood clearance of biotinylated IgG after infusion of avidin. J. Nucl. Med., 30: 66-69, 1989.
9. Breitz, H. B., Weiden, P. L., Fritzberg, A. R., Reno, J. M., and Abrams, P. G. Radiolabeled monoclonal antibodies for localization and treatment of metastatic cancer. In: R. K. Oldham (ed.), Principles of Cancer Biotherapy, Ed. 3, pp. 348-368. Dordrecht, the Netherlands: Kluwer Academic Publishers, 1998.
10. Okabe, T., Kaizu, T., Fujisawa, J., Watanabe, J., Kojima, K. Yamashita, T., and Takaku, F. Monoclonal antibodies to surface antigens of small cell carcinoma of the lung. Cancer Res., 44: 5273-5278, 1984.
11. Pearson, J. W., Sivan, G., Manger, R., Wiltrout, R. H., Morgan, A. C., Jr., and Longo, D. Enhanced therapeutic efficacy of an immunotoxin in combination with chemotherapy against an i.p. human tumor xenograft in athymic mice. Cancer Res., 49: 4990-4995, 1989.
12. 186 Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res., 51: 676-681, 1991.
13. 90Y-DOTA-biotin. J. Nucl. Med., in press, 2000.
14. Press, O. W., Eary, J. F., Appelbaum, F. R., and Bernstein, I. D. Radiolabeled antibody therapy of lymphomas. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Biological Therapy of Cancer, pp. 1-13. Philadelphia: J. B. Lippincott Company, 1994.
15. Simpkin, D. J., and Mackie, T. R. EGS4 Monte Carlo determination of the β dose kernel in water. Med. Phys. (NY), 17: 179-186, 1990.
16. Prestwich, W. V., Nunes, J., and Kwok, C. S. Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J. Nucl. Med., 30: 1036-1046, 1989.
17. Meares, C. F., Moi, M. K., Diril, H., Kukis, D. L., McCall, M. J., Deshapnde, S. V., DeNardo, S. J., Snook, D., and Epenetos, A. A. Macrocyclic chelates of radiometals for diagnosis and therapy. Br. J. Cancer. 62 (Suppl. X): 21-26, 1990.
18. 90Yttrium. Proc. Am. Soc. Clin. Oncol., 17: 438a, 1998.
19. Pearson, T. C., Guthrie, D. L., Simpson, J., Chinn, S., Barosi, G., Ferrant, A., Lewis, S. M., and Najean, Y. Interruption of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Hematology. Br. J. Haematol., 89: 748-756, 1995.
20. 90Y-DOTA-biotin with pretargeted NR-LU-10/SA. Cancer Biother. Radiopharm., 14: 381-395, 1999.
21. International Commission on Radiation Units and Measurements (ICRU). Methods of assessment of absorbed dose in clinical use of radionuclides. ICRU Report No. 32. Washington, DC: International Commission on Radiation Units and Measurements, 1979.
22. National Council on Radiation Protection and Measurements (NCRP). The experimental basis for absorbed dose calculations in medical uses of radionuclides. NCRP Report No. 83, Bethesda, Maryland: National Council on Radiation Protection and Measurements, 1985.
23. Loevinger, R., Budinger, T. F., and Watson, E. E. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine, Inc., 1988.
24. Fisher, D. R., Badger, C. C., Breitz, H., Eary, J. F., Durham, J. S., Hui, T. E., Hill, R. L., and Neip, W. B. Internal radiation dosimetry for clinical testing of radiolabeled monoclonal antibodies. Antib. Immunoconjug. Radiopharm., 4: 655-664, 1991.
25. Siegel, J. A., Wessels, B. W., Watson, E. E., Stabin, M. G., Vriesendorp, H. M., Bradley, E. W., Badger, C. C., Brill, A. B., Kwok, C. S., Stickney, D. R., Eckerman, K. F., Fisher, D. R., Buchsbaum, D. J., and Order, S. E. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antib. Immunuconjug. Radiopharm., 3: 213-233, 1990.
26. Breitz, H. B., Fisher, D. R., and Wessels, B. W. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J. Nucl. Med., 39: 1746-1751, 1998.
27. International Commission on Radiological Protection. Limits for intakes of radionuclides by workers. ICRP Publication 30. Oxford: Pergamon Press, 1979.
28. Fisher, D. R., Rajon, D., Bolch, W. E., and Breitz, H. D. Dosimetry model for radiolabeled antibodies in gastro-intestinal mucosa. Cancer Biother. Radiopharm., 13: 301, 1998.
29. Breitz, H. B., Weiden, P. L., Vanderheyden, J-L., Appelbaum, J. W., Bjorn, M. J., Fer, M. F., Wolf, S. B., Ratliff, B. A., Seiler C. A., and Foisie, D. C. Clinical experience with Re-186-labeled monoclonal antibodies for radioimmunotherapy: results of Phase I trials. J. Nucl. Med., 33: 1099-1112, 1992.
30. Rubin, P., Constine, L. S., and Williams, J. P. Late effects of cancer treatment: radiation and drug toxicity. In: C. A. Perez and L. W. Brady (eds.), Principles and Practice of Radiation Oncology, Ed. 3, pp. 155-211. New York: Lippincott-Raven, 1998.
31. Hoppe, R. T. The non-Hodgkin's lymphomas: pathology, staging and treatment. Curr. Prob. Cancer, 6: 364-447, 1987.